ClinicalTrials.gg
Active, not recruitingNCT03759431VOCALUpdated Mar 21, 2025

Vocal-cord vs. Complete Laryngeal Radiotherapy for Early Glottic Cancer

A Phase 2 interventional study of Vocal-cord Radiotherapy and Complete Larynx Radiotherapy in Cancer Neck, Larynx Cancer and Glottis Tumor, sponsored by Centre hospitalier de l'Université de Montréal (CHUM). Active, not recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-21.

Primary conditionLaryngeal NeoplasmsRegistry: Head and Neck NeoplasmsReclassifiedWhy we changed it
Registry
Head and Neck Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Laryngeal Neoplasms
Why
  1. The study's listed conditions name Laryngeal Neoplasms, a narrower term within Head and Neck Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Centre hospitalier de l'Université de Montréal (CHUM) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
155
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicentrer, randomized Bayesian Phase II trial for patients with early stage (T1N0) glottic squamous cell carcinoma treated with radical radiotherapy. The primary objective is to assess the non-inferiority of local control achieved with vocal-cord only radiotherapy (VC-RT) compared to complete larynx radiotherapy (CL-RT) in T1N0 glottic laryngeal squamous cell cancer, measured at 2-years after treatment. Secondary outcomes include overall survival, as well as voice impairment, dysphagia and quality of life, measured respectively by the voice handicap index -10 (VHI-10), the MD Anderson Dysphagia Inventory (MDADI) and the MD Anderson Symptom Inventory- Head and Neck module (MDASI-HN). Patients will be randomized in a 1:3 ratio to CL-RT (39 patients) and VC-RT (116 patients) arms. There will be stratification by tumor stage (T1a/T1b) and by institution. An interim analysis is planned after the first 55 patients enrolled on the experimental arm have a 6-month follow-up.

02

Conditions studied

  • Cancer Neck
  • Larynx Cancer
  • Glottis Tumor

Browse trials for

03

In context

Laryngeal Neoplasms Reclassified

258 studies on the registry are indexed under Laryngeal Neoplasms; 69 are open to participants now.

This study's planned enrollment of 155 is above the median of 47 across 180 interventional studies indexed under Laryngeal Neoplasms.

Browse Laryngeal Neoplasms studies →

Lead sponsor

Centre hospitalier de l'Université de Montréal (CHUM) is the lead sponsor of 376 studies on the registry; 110 are open to participants now.

Compared within Laryngeal Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Head and Neck Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stage T1a-b N0 of the true vocal cords planned for definitive RT
  • Patient not candidate for laser surgery or declined laser surgery
  • -confirmed squamous cell carcinoma, including verrucous carcinoma
  • performance status 0-2
  • Ability to provide written .

Exclusion criteria

Exclusion Criteria:

  • Previous irradiation of the head and neck (HNC) region
  • Pregnancy or breastfeeding
  • Any medical condition that represents, in the opinion of the investigator, a to radiotherapy or would prevent follow-up after radiotherapy.
  • Prior invasive (except non-melanomatous skin cancer) unless disease free for a minimum of 2 years.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
155 participants (estimated)

Study arms

  • Experimental
    Vocal-cord Radiotherapy

    Radiation: Vocal-cord Radiotherapy

  • Active comparator
    Complete Larynx Radiotherapy

    Radiation: Complete Larynx Radiotherapy

Interventions

  • RadiationVocal-cord Radiotherapy

    Focal radiotherapy limited to the involved vocal cord(s) plus additional margins accounting for respiration and set-up errors.

  • RadiationComplete Larynx Radiotherapy

    Radiotherapy to the entire larynx, with target volumes defined to lead to traditional volumes from conventional complete larynx radiotherapy.

06

What researchers measure

Primary outcomes

  1. Local control

    Local control rate of vocal-cord radiotherapy

    Time frame: At 2-year follow-up

Secondary outcomes

  1. Voice Handicap Index-10 score

    Scores are rated on a 0-4 scale to indicate the presence and severity of the symptoms. Lower scores represent better functioning and quality of life.

    Time frame: Week 0 post-treatment, and at 2-month, 6-month, 1-year and 2-year follow-up

  2. MD Anderson Dysphagia Inventory score

    Overall score ranges from 0 to 100, with higher score representing better functioning and quality of life.

    Time frame: Week 0 post-treatment, and at 2-month, 6-month, 1-year and 2-year follow-up

  3. MD Anderson Symptom Inventory-Head & Neck score

    The core and head and neck cancer specific symptoms are rated on a 0-10 scale to indicate the presence and severity of the symptoms. Lower scores represent better functioning and quality of life.

    Time frame: Week 0 post-treatment, and at 2-month, 6-month, 1-year and 2-year follow-up

  4. Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V)

    The attributes of CAPE-V are: (a) Overall Severity; (b) Roughness; (c) Breathiness; (d) Strain; (e) Pitch; and (f) Loudness. Each attribute is displayed accompanied by a 100- millimeter line forming a visual analog scale, with a higher score representing more deviant voice attributes.

    Time frame: Week 0 post-treatment and at 6-month follow-up

  5. Rates of acute toxicity as per CTCAE v5.0

    Time frame: Week 0 post-treatment and at 2-month follow-up

  6. Rates of chronic toxicity as per CTCAE v5.0

    Time frame: At 6-month, 1-year, 2-year and 5-year post-treatment

  7. Rates of new hypothyroidism

    Time frame: At 2- and 5-year follow-up

  8. Rates of cerebrovascular event (transient ischemic attack or stroke)

    Time frame: At 5-year follow-up

  9. Overall survival

    Time frame: At 2- and 5-year follow-up

  10. Time to recurrence

    Time frame: At 2- and 5-year follow-up

07

Study locations

3 sites
08

References and documents

Publications

  • Bahig H, Rosenthal DI, Nguyen-Tan FP, Fuller DC, Yuan Y, Hutcheson KA, Christopoulos A, Nichols AC, Fung K, Ballivy O, Filion E, Ng SP, Lambert L, Dorth J, Hu KS, Palma D. Vocal-cord Only vs. Complete Laryngeal radiation (VOCAL): a randomized multicentric Bayesian phase II trial. BMC Cancer. 2021 Apr 22;21(1):446. doi: 10.1186/s12885-021-08195-8. PubMed 33888069 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2018 (actual). Primary completion is estimated for Dec 2026, 98 months after the start.

Of 30 phase 2 interventional studies under Laryngeal Neoplasms, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 55 and three quarters within 82. This study's planned 98 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2018
First posted
Nov 30, 2018
StartActual
Oct 11, 2018
Primary completionEst.
Dec 12, 2026
CompletionEst.
Dec 12, 2026
Last update
Mar 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03759431
Collaborators
London Health Sciences Centre, M.D. Anderson Cancer Center
Responsible party
Sponsor
First posted
Nov 30, 2018
Start date
Oct 11, 2018
Primary completion
Dec 12, 2026 (estimated)
Completion
Dec 12, 2026 (estimated)
Last update
Mar 21, 2025

Study contacts

Houda Bahig
study chair · Centre hospitalier de l'Université de Montréal (CHUM)
David Palma
study chair · London Health Sciences Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion